Novartis agrees to pay $347 million to settle bribery allegations

pharmafile | June 26, 2020 | News story | Medical Communications Greece, Novartis, bribery 

Novartis and its former eye care unit Alcon have agreed to pay a combined $347 million to resolve allegations that the companies ran bribery schemes in hospitals and clinics in Greece, Vietnam and South Korea.

This payment brings an end to investigations by both the US Department of Justice and the Securities and Exchange Commission into alleged criminal and civil violations of the Foreign Corrupt Practices Act (FCPA). The companies entered into a prosecution agreements to resolve the charges.

This investigation into Novartis by the US began in 2016, and Greek prosecutors also sent a report in 2018 to its parliament alleging that the companies had bribed doctors and politicians to fix the prices of its drugs. These charges have long been denied by Novartis and Alcon.

But the agreements detailed a scheme by Alcon to carry out the bribery in state-controlled hospitals throughout Greece, with the expectation that these employees would increase the number prescriptions they wrote for Lucentis, a medication used to treat certain eye conditions. The bribery scheme also saw a conspiracy to violate the FCPA, including an attempt to hide the schemes by causing Novartis to record false books in its records which constituted a second conspiracy to violate the antibribery statue.

Alcon agreed to pay a criminal penalty of $225 million, while its former parent company Novartis agreed to pay more than $112 million which representing the amount of illicit profits.

Conor Kavanagh

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Novartis to acquire MorphoSys AG for €2.7bn

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …

Latest content